Case Number 12013
Request Date 17/07/2026
Completion Date 24/08/2026

 

Details of the Request

I am writing to submit a new FOI request about dermatology services at your NHS organisation.

1. In the last 6 months (November 2025 to April 2026), how many adult patients were treated by the dermatology department, excluding patients referred for cancer / suspected cancer?

2. Do you run a specific clinic for patients with atopic dermatitis?

3. In the last 6 months (November 2025 to April 2026), how many adult patients with atopic dermatitis were treated by the dermatology department?

4. In the last 6 months (November 2025 to April 2026), how many adult patients with atopic dermatitis were treated with the following products:

  1. Immunosuppressants (Azathioprine, Ciclosporin, Methotrexate, Mycophenolate mofetil, Pimecrolimus, or Tacrolimus)
  2. Abrocitinib
  3. Baricitinib
  4. Dupilumab
  5. Lebrikizumab
  6. Tralokinumab
  7. Upadacitinib
  8. Nemolizumab
  9. Delgocitinib

 

5. In the last 6 months (November 2025 to April 2026), how many adult patients with atopic dermatitis were started on the following products:

  1. Immunosuppressants (Azathioprine, Ciclosporin, Methotrexate, Mycophenolate mofetil, Pimecrolimus, or Tacrolimus)
  2. Abrocitinib
  3. Baricitinib
  4. Dupilumab
  5. Lebrikizumab
  6. Tralokinumab
  7. Upadacitinib
  8. Nemolizumab
  9. Delgocitinib

 

Details of the Response

1. In the last 6 months (November 2025 to April 2026), how many adult patients were treated by the dermatology department, excluding patients referred for cancer / suspected cancer? 

119

 

2. Do you run a specific clinic for patients with atopic dermatitis?

No

 

3. In the last 6 months (November 2025 to April 2026), how many adult patients with atopic dermatitis were treated by the dermatology department?

5

 

4. In the last 6 months (November 2025 to April 2026), how many adult patients with atopic dermatitis were treated with the following products:

  1. Immunosuppressants (Azathioprine, Ciclosporin, Methotrexate, Mycophenolate mofetil, Pimecrolimus, or Tacrolimus) = 0
  2. Abrocitinib = 0
  3. Baricitinib = 0
  4. Dupilumab = <5
  5. Lebrikizumab = <5
  6. Tralokinumab = 0
  7. Upadacitinib = 0
  8. Nemolizumab = 0
  9. Delgocitinib = 0

 

5. In the last 6 months (November 2025 to April 2026), how many adult patients with atopic dermatitis were started on the following products:

  1. Immunosuppressants (Azathioprine, Ciclosporin, Methotrexate, Mycophenolate mofetil, Pimecrolimus, or Tacrolimus)
  2. Abrocitinib = 0
  3. Baricitinib = 0
  4. Dupilumab = <5
  5. Lebrikizumab = <5
  6. Tralokinumab = 0
  7. Upadacitinib = 0
  8. Nemolizumab = 0
  9. Delgocitinib = 0

 

 

Protecting Your Online Privacy
Protecting Your Online Privacy

This Ashford and St Peter's website uses cookies to track visitor numbers. Find out more in our Cookies Policy and Privacy Policy. You can also read our Accessibility Statement and Privacy Notice for your information.